semaglutide cardiovascular outcomes 2025 news today New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis SOUL: Oral Semaglutide Bests Usual

Semaglutide is ideal for individuals with a body mass index (BMI) of 30 or greater or adults with a BMI of 27 and at least one complication related to body weight, such as hypertension, insulin resistance, high cholesterol, or heart disease

Treating metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis

GoodRx, a platform for medication savings, shares what you should know about oral semaglutide (Wegovy) for weight loss how it works, how to take it, and more

Arturi, F

Requires Ongoing Use: For continued benefits, patients often stay on it long-term under medical supervision

11 CRISPR-based studies further demonstrate that interferon regulatory factor 1 (IRF1), a key transcription factor downstream of IFN-, is indispensable for maintaining tumor immunogenicity